VIVORYON THERAPEUTICS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.752 EUR | -1.44% |
|
-9.40% | -90.76% |
| Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
| Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
Presentation Operator MessageOperator (Operator)Good day and welcome to the Vivoryon Therapeut...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Calendar
2024-05-23
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.752
EUR
Average target price
41.57
EUR
Spread / Average Target
+5,427.48%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -90.76% | 21.62M | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
- Stock Market
- Equities
- VVY Stock
- News Vivoryon Therapeutics N.V.
- Transcript : Vivoryon Therapeutics AG, H1 2020 Earnings Call, Aug 27, 2020